Patents by Inventor Hampar Karageozian
Hampar Karageozian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170239287Abstract: Compositions comprising a glycosaminoglycan (e.g., a hyaluronan, hyaluronic acid, hyaluronate, sodium hyaluronate, dermatan sulfate, karatan sulfate, chondroitin 6-sulfate, heparin, etc.) in combination with at least one component selected from; i) polyglycols (e.g., polyethylene glycol), ii) long chain hydroxy polyanionic polysaccharides (e.g., dextran, sodium alginate, alginic acid, propylene glycol alginate, carboxymethyl cellulose and carboxyethyl cellulose, hydroxyl ethyl starch, hydroxyl propyl methyl cellulose, hydroxy propyl ethyl cellulose, hydroxy propyl cellulose, methyl cellulose, polylysine, polyhistidine, polyhydroxy proline, poly ornithine, polyvinyl pyrolidone, polyvinyl alcohol, chitosan, etc.) and iii) long chain Nitrogen containing polymers (e.g., Polylysine, Polyvinylpyrrolidone, and polyvinyl alcohol). The invention also includes methods for using such compositions (e.g., as substance delivery materials, tissue fillers or bulking agents, as moistening or hydrating agents, etc.Type: ApplicationFiled: November 7, 2016Publication date: August 24, 2017Inventors: Hampar Karageozian, John Park
-
Patent number: 9511088Abstract: Compositions comprising a glycosaminoglycan (e.g., a hyaluronan, hyaluronic acid, hyaluronate, sodium hyaluronate, dermatan sulfate, karatan sulfate, chondroitin 6-sulfate, heparin, etc.) in combination with at least one component selected from; i) polyglycols (e.g., polyethylene glycol), ii) long chain hydroxy polyanionic polysaccharides (e.g., dextran, sodium alginate, alginic acid, propylene glycol alginate, carboxymethyl cellulose and carboxyethyl cellulose, hydroxyl ethyl starch, hydroxyl propyl methyl cellulose, hydroxy propyl ethyl cellulose, hydroxy propyl cellulose, methyl cellulose, polylysine, polyhistidine, polyhydroxy proline, poly ornithine, polyvinyl pyrolidone, polyvinyl alcohol, chitosan, etc.) and iii) long chain Nitrogen containing polymers (e.g., Polylysine, Polyvinylpyrrolidone, and polyvinyl alcohol). The invention also includes methods for using such compositions (e.g., as substance delivery materials, tissue fillers or bulking agents, as moistening or hydrating agents, etc.Type: GrantFiled: April 14, 2014Date of Patent: December 6, 2016Assignee: S.K. Pharmaceuticals, Inc.Inventors: Hampar Karageozian, John Park
-
Publication number: 20150056272Abstract: Antimicrobial/pharmaceutical preparations (e.g., solutions, gels, ointments, creams, sustained release preparations, etc.) which comprise chlorite (e.g., a metal salt of a chlorite) in combination with a peroxy compound (e.g., hydrogen peroxide), and methods for using such preparations for disinfection of articles or surfaces (e.g., contact lenses, counter tops, etc.), antisepsis of skin or other body parts, prevention or deterrence of scar formation and/or treatment and prophylaxis of dermal (i.e., skin or mucous membrane) disorders (e.g., wounds, burns, infections, cold sores, ulcerations, psoriasis, acne, or other scar-forming lesions).Type: ApplicationFiled: September 10, 2014Publication date: February 26, 2015Inventor: Hampar Karageozian
-
Publication number: 20140343013Abstract: Compositions comprising a glycosaminoglycan (e.g., a hyaluronan, hyaluronic acid, hyaluronate, sodium hyaluronate, dermatan sulfate, karatan sulfate, chondroitin 6-sulfate, heparin, etc.) in combination with at least one component selected from; i) polyglycols (e.g., polyethylene glycol), ii) long chain hydroxy polyanionic polysaccharides (e.g., dextran, sodium alginate, alginic acid, propylene glycol alginate, carboxymethyl cellulose and carboxyethyl cellulose, hydroxyl ethyl starch, hydroxyl propyl methyl cellulose, hydroxy propyl ethyl cellulose, hydroxy propyl cellulose, methyl cellulose, polylysine, polyhistidine, polyhydroxy proline, poly ornithine, polyvinyl pyrolidone, polyvinyl alcohol, chitosan, etc.) and iii) long chain Nitrogen containing polymers (e.g., Polylysine, Polyvinylpyrrolidone, and polyvinyl alcohol). The invention also includes methods for using such compositions (e.g., as substance delivery materials, tissue fillers or bulking agents, as moistening or hydrating agents, etc.Type: ApplicationFiled: April 14, 2014Publication date: November 20, 2014Applicant: S.K. PharmaceuticalsInventors: Hampar Karageozian, John Park
-
Publication number: 20130102561Abstract: Compositions comprising a glycosaminoglycan (e.g., a hyaluronan, hyaluronic acid, hyaluronate, sodium hyaluronate, dermatan sulfate, karatan sulfate, chondroitin 6-sulfate, heparin, etc.) in combination with at least one component selected from; i) polyglycols (e.g., polyethylene glycol), ii) long chain hydroxy polyanionic polysaccharides (e.g., dextran, sodium alginate, alginic acid, propylene glycol alginate, carboxymethyl cellulose and carboxyethyl cellulose, hydroxyl ethyl starch, hydroxyl propyl methyl cellulose, hydroxy propyl ethyl cellulose, hydroxy propyl cellulose, methyl cellulose, polylysine, polyhistidine, polyhydroxy proline, poly ornithine, polyvinyl pyrolidone, polyvinyl alcohol, chitosan, etc.) and iii) long chain Nitrogen containing polymers (e.g., Polylysine, Polyvinylpyrrolidone, and polyvinyl alcohol). The invention also includes methods for using such compositions (e.g., as substance delivery materials, tissue fillers or bulking agents, as moistening or hydrating agents, etc.Type: ApplicationFiled: October 9, 2012Publication date: April 25, 2013Applicant: S.K. PHARMACEUTICALSInventors: Hampar Karageozian, John Park
-
Patent number: 8288362Abstract: Compositions comprising a glycosaminoglycan (e.g., a hyaluronan, hyaluronic acid, hyaluronate, sodium hyaluronate, dermatan sulfate, karatan sulfate, chondroitin 6-sulfate, heparin, etc.) in combination with at least one component selected from; i) polyglycols (e.g., polyethylene glycol), ii) long chain hydroxy polyanionic polysaccharides (e.g., dextran, sodium alginate, alginic acid, propylene glycol alginate, carboxymethyl cellulose and carboxyethyl cellulose, hydroxyl ethyl starch, hydroxyl propyl methyl cellulose, hydroxy propyl ethyl cellulose, hydroxy propyl cellulose, methyl cellulose, polylysine, polyhistidine, polyhydroxy proline, poly ornithine, polyvinyl pyrolidone, polyvinyl alcohol, chitosan, etc.) and iii) long chain Nitrogen containing polymers (e.g., Polylysine, Polyvinylpyrrolidone, and polyvinyl alcohol). The invention also includes methods for using such compositions (e.g., as substance delivery materials, tissue fillers or bulking agents, as moistening or hydrating agents, etc.).Type: GrantFiled: November 14, 2007Date of Patent: October 16, 2012Assignee: S.K. Pharmaceuticals, Inc.Inventors: Hampar Karageozian, John Park
-
Publication number: 20090042834Abstract: Compositions comprising a glycosaminoglycan (e.g., a hyaluronan, hyaluronic acid, hyaluronate, sodium hyaluronate, dermatan sulfate, karatan sulfate, chondroitin 6-sulfate, heparin, etc.) in combination with at least one component selected from; i) polyglycols (e.g., polyethylene glycol), ii) long chain hydroxy polyanionic polysaccharides (e.g., dextran, sodium alginate, alginic acid, propylene glycol alginate, carboxymethyl cellulose and carboxyethyl cellulose, hydroxyl ethyl starch, hydroxyl propyl methyl cellulose, hydroxy propyl ethyl cellulose, hydroxy propyl cellulose, methyl cellulose, polylysine, polyhistidine, polyhydroxy proline, poly ornithine, polyvinyl pyrolidone, polyvinyl alcohol, chitosan, etc.) and iii) long chain Nitrogen containing polymers (e.g., Polylysine, Polyvinylpyrrolidone, and polyvinyl alcohol). The invention also includes methods for using such compositions (e.g., as substance delivery materials, tissue fillers or bulking agents, as moistening or hydrating agents, etc.Type: ApplicationFiled: November 14, 2007Publication date: February 12, 2009Applicant: S.K. Pharmaceuticals, Inc.Inventors: Hampar Karageozian, John Park
-
Publication number: 20060034822Abstract: A thimerosal-free hyaluronidase preparation wherein the preferred hyaluronidase enzyme is devoid of molecular weight fractions below 40,000 MW, between 60-70,000 MW and above 100,000 MW. Also disclosed is a method for accelerating the clearance of hemorrhagic blood from the vitreous humor of the eye, said method comprising the step of contacting at least one hemorrhage-clearing enzyme (e.g., a ?-glucuronidase, matrix metalloproteinase, chondroitinase, chondroitin sulfatase or protein kinase) with the vitreous humor in an amount which is effective to cause accelerated clearance of blood therefrom.Type: ApplicationFiled: August 15, 2005Publication date: February 16, 2006Inventors: Hampar Karageozian, Vicken Karageozian, Maria Kenney, Jose Gutierrez Flores, Gabriel Carpio Aragon, Anthony Nesburn
-
Publication number: 20060029571Abstract: Stabilized hyaluronan preparations wherein hyaluronan is combined with a polyglycol, such as polyethylene glycol. Stabilized hyaluronan preparations of this invention may maintain their viscosity and lubricity for extended time periods (e.g., 2 years) without requiring refrigeration or special storage conditions.Type: ApplicationFiled: May 9, 2005Publication date: February 9, 2006Applicant: S.K. Pharmaceuticals, Inc.Inventors: Hampar Karageozian, John Park
-
Publication number: 20050069531Abstract: An enzymatic method is provided for treating ophthalmic disorders of the mammalian eye. Prevention of neovascularization and the increased rate of clearance from the vitreous of materials toxic to retina is accomplished by administering an amount of hyaluronidase effective to liquefy the vitreous humor of the treated eye without causing toxic damage to the eye. Liquefaction of the vitreous humor increases the rate of liquid exchange from the vitreal chamber. This increase in exchange removes those materials and conditions whose presence causes ophthalmological and retinal damage.Type: ApplicationFiled: November 12, 2004Publication date: March 31, 2005Inventors: Hampar Karageozian, Vicken Karageozian, Maria Kenney, Jose Flores, Gabriel Carpio Aragon, Anthony Nesburn
-
Patent number: 6863886Abstract: An enzymatic method is provided for treating ophthalmic disorders of the mammalian eye. Prevention of neovascularization and the increased rate of clearance from the vitreous of materials toxic to retina is accomplished by administering an amount of hyaluronidase effective to liquefy the vitreous humor of the treated eye without causing toxic damage to the eye. Liquefaction of the vitreous humor increases the rate of liquid exchange from the vitreal chamber. This increase in exchange removes those materials and conditions whose presence causes ophthalmological and retinal damage.Type: GrantFiled: February 21, 2003Date of Patent: March 8, 2005Assignee: Advanced Corneal SystemsInventors: Hampar Karageozian, Vicken Karageozian, Maria C. Kenney, Jose L. G. Flores, Gabriel Arturo Carpio Aragon, Anthony B. Nesburn
-
Patent number: 6737075Abstract: The invention disclosed herein relates to biochemical methods for the elimination of corneal collagen fiber disorganization to improve vision. Disorganization of corneal collagen fibers is seen in corneal scars, corneal opacification and corneal haze. In addition, the invention relates to biochemical methods for the elimination of corneal collagen fiber disorganization resulting from accidental traumatic injury to the cornea and from refractive surgery for such as radial keratotomy (RK), photorefractive keratectomy (PRK), and laser in situ keratomileusis (LASIK) so as to improve visual acuity and quality of vision.Type: GrantFiled: October 10, 2001Date of Patent: May 18, 2004Assignee: Ista Pharmaceuticals, Inc.Inventor: Hampar Karageozian
-
Publication number: 20030170224Abstract: An enzymatic method is provided for treating ophthalmic disorders of the mammalian eye. Prevention of neovascularization and the increased rate of clearance from the vitreous of materials toxic to retina is accomplished by administering an amount of hyaluronidase effective to liquefy the vitreous humor of the treated eye without causing toxic damage to the eye. Liquefaction of the vitreous humor increases the rate of liquid exchange from the vitreal chamber. This increase in exchange removes those materials and conditions whose presence causes ophthalmological and retinal damage.Type: ApplicationFiled: February 21, 2003Publication date: September 11, 2003Inventors: Hampar Karageozian, Vicken Karageozian, Maria C. Kenney, Jose L.G. Flores, Gabriel Arturo Carpio Aragon, Anthony B. Nesburn
-
Patent number: 6610292Abstract: An enzymatic method is provided for treating ophthalmic disorders of the mammalian eye. Prevention of neovascularization and the increased rate of clearance from the vitreous of materials toxic to the retina is accomplished by administering an amount of hyaluronidase effective to liquefy the vitreous humor of the treated eye without causing toxic damage to the eye. Liquefaction of the vitreous humor increases the rate of liquid exchange from the vitreal chamber. This increase in exchange removes those materials and conditions whose presence causes ophthalmological and retinal damage.Type: GrantFiled: November 19, 1999Date of Patent: August 26, 2003Assignee: ISTA Pharmaceuticals, Inc.Inventors: Hampar Karageozian, Vicken Karageozian, Maria C. Kenney, Jose L. G. Flores, Gabriel Arturo Carpio Aragon, Anthony B. Nesburn
-
Publication number: 20020164316Abstract: An enzymatic method is provided for treating ophthalmic disorders of the mammalian eye. Prevention of neovascularization and the increased rate of clearance from the vitreous of materials toxic to retina is accomplished by administering an amount of hyaluronidase effective to liquefy the vitreous humor of the treated eye without causing toxic damage to the eye. Liquefaction of the vitreous humor increases the rate of liquid exchange from the vitreal chamber. This increase in exchange removes those materials and conditions whose presence causes ophthalmological and retinal damage.Type: ApplicationFiled: November 19, 1999Publication date: November 7, 2002Inventors: HAMPAR KARAGEOZIAN, VIKEN KARAGEOZIAN, MARIA C. KENNEY, JOSE L. G. FLORES, GABRIEL ARTURO CARPIO ARAGON, ANTHONY B. NESBURN
-
Publication number: 20020119141Abstract: The invention disclosed herein relates to biochemical methods for the elimination of corneal collagen fiber disorganization to improve vision. Disorganization of corneal collagen fibers is seen in corneal scars, corneal opacification and corneal haze. In addition, the invention relates to biochemical methods for the elimination of corneal collagen fiber disorganization resulting from accidental traumatic injury to the cornea and from refractive surgery for such as radial keratotomy (RK), photorefractive keratectomy (PRK), and laser in situ keratomileusis (LASIK) so as to improve visual acuity and quality of vision.Type: ApplicationFiled: October 10, 2001Publication date: August 29, 2002Inventor: Hampar Karageozian
-
Patent number: 6132735Abstract: A method and apparatus for correcting refractive errors of the eye are disclosed. Accelerated reshaping of the corneal tissue is accomplished by administering one or more enzymes and/or other agents to the eye which temporarily soften the cornea. The cornea is thereafter fitted with a rigid contact lens or a series of lenses which have a concave curvature that will correct a refractive error. The softened cornea then rapidly reshapes its convex curvature to the concave curvature of the contact lens or series of lenses, thereby rendering the eye emmetropic. The enzymes and/or other agents then dissipate from the cornea, and the cornea "hardens" to retain the new emmetropic shape. After "hardening" has occurred, the lens rendering the eye emmetropic is removed.Type: GrantFiled: September 18, 1997Date of Patent: October 17, 2000Assignee: ISTA Pharmaceutical, Inc.Inventors: Donald H. Harris, Charles May, Hampar Karageozian
-
Patent number: 5626865Abstract: A method and apparatus for correcting refractive errors of the eye are disclosed. Accelerated reshaping of the corneal tissue is accomplished by administering one or more enzymes and/or other agents to the eye which temporarily soften the cornea. The cornea is thereafter fitted with a rigid contact lens or a series of lenses which have a concave curvature that will correct a refractive error. The softened cornea then rapidly reshapes its convex curvature to the concave curvature of the contact lens or series of lenses, thereby rendering the eye emmetropic. The enzymes and/or other agents then dissipate from the cornea, and the cornea "hardens" to retain the new emmetropic shape. After "hardening" has occurred, the lens rendering the eye emmetropic is removed.Type: GrantFiled: July 18, 1994Date of Patent: May 6, 1997Assignee: Advanced Corneal Systems, Inc.Inventors: Donald H. Harris, Charles May, Hampar Karageozian
-
Patent number: 5338480Abstract: Compositions and methods to clean contact lenses are disclosed. In one embodiment, the present composition comprises at least at least one enzyme capable of removing debris from a contact lens and at least one disinfectant destroying component capable of destroying a contact lens disinfectant which is incompatible with the at least one enzyme. The composition is structured so that the at least one enzyme is released in a liquid medium containing the contact lens disinfectant at substantially the same time or after the at least one disinfectant destroying component is released in the liquid medium, thereby allowing the at least one enzyme to remove debris from a contact lens in the liquid medium.Type: GrantFiled: March 4, 1991Date of Patent: August 16, 1994Assignee: Allegan, Inc.Inventors: Anthony J. Dziabo, Hampar Karageozian, Paul S. Ripley, Sam W. Lam, J. Abraham Espiritu
-
Patent number: 5279673Abstract: A method for disinfecting a lens is disclosed. The method comprises contacting a lens to be disinfected in a liquid medium with at least one chlorine dioxide precursor in the presence of at least one acidic component effective to increase the rate of formation of chlorine dioxide from the chlorine dioxide precursor, thereby disinfecting the lens; and adjusting the acidity of the liquid medium containing the disinfected lens. Compositions useful in the above-noted method are also disclosed.Type: GrantFiled: January 5, 1990Date of Patent: January 18, 1994Assignee: Allergan, Inc.Inventors: Anthony J. Dziabo, Hampar Karageozian, Paul S. Ripley